The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TECX | +57.95% | -73.59% | -23.36% | +64% |
| S&P | +17.45% | +75.43% | +11.88% | +23% |
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$333.00K | 34.4% |
| Market Cap | $390.42M | -42.7% |
| Market Cap / Employee | $6.51M | 0.0% |
| Employees | 60 | 17.6% |
| Net Income | -$19,226.00K | -55.4% |
| EBITDA | -$21,183.00K | -57.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $254.39M | 80.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $43.00K | -91.7% |
| Short Term Debt | $1.23M | -55.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.83% | 3.2% |
| Return On Invested Capital | 521.34% | 572.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14,461.00K | 14.0% |
| Operating Free Cash Flow | -$14,461.00K | 14.0% |
| Metric | Q1 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1.85 | - | |||
| Price to Book | 1.87 | 1.23 | 1.03 | 1.46 | -67.77% |
| Price to Tangible Book Value | 1.87 | 1.23 | 1.03 | 1.46 | -67.77% |
| Enterprise Value to EBITDA | -0.01 | -3.90 | -1.20 | -6.48 | -83.96% |
| Return on Equity | -30.1% | -29.3% | -32.2% | -37.8% | -10.15% |
| Total Debt | $2.63M | $1.94M | $1.24M | $1.28M | -61.37% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
